KKKatarzyna Krenke

Katarzyna Krenke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katarzyna Krenke has a total of 288 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Case Report: Epstein‐Barr Virus (EBV) and Acid Sphingomyelinase Deficiency (ASMD) Type A/B: Possible Interaction

    by Anna Wiesner, Katarzyna Jończyk‐Potoczna, Marcin Mikoś, Katarzyna Krenke, Maciej Pronicki, Renata Langfort, Monika Duś‐Żuchowska, Anna BręBorowicz, Irena Wojsyk‐Banaszak

  • Malnutrition in childhood interstitial lung diseases is associated with reduced lung function and greater disease severity: insights from the chILD-EU registry

    by Tugba Ramasli Gursoy, Nagehan Emiralioglu, Matthias Griese, Elias Seidl, Julia Rodler, Nicolaus Schwerk, Julia Carlens, Martin Wetzke, Nadia Nathan, Steve Cunningham, et al.


  • Health-related quality of life in childhood interstitial lung disease

    by Matthias Griese, Mandy Niemitz, Katrin Erlewein, Srdjan Micic, Julia Rodler, Julia Carlens, Honorata Marczak, Joanna Lange, Katarzyna Krenke, Nagehan Emiralioğlu, et al.

    Background: Childhood interstitial lung diseases (chILD) encompass a diverse group of rare, chronic respiratory disorders. While treatment options are limited, evaluating health-related quality of life (HRQoL) has become a vital approach for clinical monitoring. This study aims to enhance our understanding of the medical and sociodemographic factors influencing HRQoL in chILD. Methods: This study used prospectively obtained data from the chILD-EU Register. Caregivers were handed validated, age-specific HRQoL questionnaires (the chILD-specific questionnaire and the generic Pediatric Quality of Life Questionnaire (PedsQL) 4.0 questionnaire). The scores were linearly transformed from a 5-point scale to a percentage scale ranging from 0% to 100%. We used exploratory univariate analyses and multivariable ordinary least squares (OLS) regression models on cross-sectional data to investigate the associations between subjects’ clinical features and HRQoL scores. Results: 424 patients from 10 European countries and 48 study sites were included in the final analysis. The most relevant factors associated with lower HRQoL scores for the chILD-specific questionnaire and the PedsQL 4.0 Total Score, as identified in the univariate analysis and confirmed in the multivariable OLS regression model, were “inpatient medical care in the last 3 months” (−13.6%; p<0.0001 and −11.4%; p<0.0001, respectively) and “failure to thrive” (−9.1%; p=0.0014 and −12.1%; p<0.0001, respectively). Among subjects old enough for pulmonary function testing (PFT) (n=162), we observed only a weak correlation between PFT results and different HRQoL scores. Conclusions: The main factors linked to reduced HRQoL scores were prior inpatient treatment and failure to thrive. Further interventional studies should determine whether addressing these factors can enhance HRQoL scores and potentially improve quality of life in chILD.


  • Open Access

    Persistent tachypnoea of infancy and neuroendocrine cell hyperplasia of infancy: from systematic review to future directions

    by Nadia Nathan, Magdalena Grochowska, Katarzyna Krenke, Ralph Epaud, Philippe Reix, Matthias Griese, Camille Louvrier, Yohan Soreze, Cécile Mulard, Barbara Donnet, et al.

    Background: Neuroendocrine hyperplasia of infancy (NEHI), also called persistent tachypnoea of infancy (PTI), is one of the most prevalent forms of childhood interstitial lung disease (chILD) and one of the few with an overall favourable prognosis. Nevertheless, there is still much to be understood about the pathophysiology of NEHI and much to be done to harmonise diagnostic work-up and management. Methods: A systematic search was conducted in PubMed, Embase, Cochrane Library, Scopus and Web of Science to identify eligible studies. Results: The results are presented in a narrative format, providing an overview of the current understanding of NEHI epidemiology, clinical presentation, investigations and outcomes. In-depth discussions include the roles of clinical assessment, chest computed tomography scan and lung biopsy, along with prospects for new diagnostic tools. Additionally, the discussion covers the pathophysiology of NEHI, focusing on the possible roles of genetic predisposition and infectious triggers. Conclusions: The morbidity of NEHI is particularly significant in the first months of life, underscoring the need for clinical and basic research to develop new targeted treatments. Some of these are discussed in this review. Finally, the improved diagnosis of this rare lung disease is facilitating the formation of new parent groups, which are becoming a crucial asset for progress.


  • Childhood Interstitial Lung Diseases: Lessons Learned From 15‐Year Observation at a Polish Referral Center

    by Honorata Marczak, Katarzyna Krenke, Katarzyna Solarska‐Rydz, Joanna Lange, Teresa Bielecka, Marek Kulus

    Background: Childhood interstitial lung diseases (chILD) are rare, chronic lung diseases characterized by symptoms such as tachypnea, dyspnea, hypoxemia, crackles, and diffuse parenchymal abnormalities on chest imaging. Objective: To evaluate the etiologic spectrum, clinical presentation, management, and outcomes of chILD at a Polish referral center. Methods: We retrospectively reviewed data from patients (0−18 years) diagnosed with chILD, admitted to the Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, from June 2009 to February 2024, classified according to the chILD‐EU categorization system. Results: A total of 275 patients (65.5% male) were included, with a median age at diagnosis of 13 months (range: 1‐221). Persistent tachypnea of infancy (PTI)/neuroendocrine cell hyperplasia of infancy (NEHI) was the most common diagnosis (52.4%), followed by disorders related to systemic diseases (11.3%) and related to exposures (10.2%). 13.8% of diseases remained undefined. The predominant symptoms included crackles (81.5%), dyspnea (72.7%) and tachypnea (68.3%). All children underwent chest computed tomography. Bronchoscopy, genetic testing, and lung biopsy were performed in 46.2%, 34.9%, and 21.4% of cases, respectively. Most children (92.7%) received some form of treatment, including inhaled bronchodilators/steroids (68.8%), systemic steroids (26.5%), long‐term macrolides (16.3%), and immunosuppressants (11.6%). Oxygen supplementation and nutritional support were required in 50.5% and 29.8% of patients, respectively. At a median follow‐up of 31.5 months, 92.9% of patients achieved clinical improvement or stabilization, and 6.2% deteriorated, including seven deaths. The 5‐year survival rate was 95.66%. Conclusion: This study highlights the significant diversity within chILD, with PTI/NEHI being the most common condition.


  • Open Access

    An update on diagnosis and treatments of childhood interstitial lung diseases

    by Honorata Marczak, Katarzyna Krenke, Matthias Griese, Julia Carlens, Elias Seidl, Carlee Gilbert, Nagehan Emiralioglu, Alba Torrent-Vernetta, Brigitte Willemse, Ralph Epaud, et al.

    Childhood interstitial lung diseases (chILDs) are rare and heterogeneous disorders associated with significant morbidity and mortality. The clinical presentation of chILD typically includes chronic or recurrent respiratory signs and symptoms with diffuse radiographic abnormalities on chest imaging. Diagnosis requires a structured, multi-step approach. Treatment options are limited, with disease-specific therapies available only in selected cases and management relying primarily on supportive care. Awareness of chILDs has been steadily increasing. New diagnoses, advanced diagnostic tests, and novel treatments are emerging each year, highlighting the importance of collaborative, multidisciplinary teams in providing comprehensive care for children and families affected by these complex conditions. On behalf of the European Respiratory Society Clinical Research Collaboration for chILD (ERS CRC chILD-EU), this review provides an updated overview of the diagnostic approach and management strategies for chILDs.


  • A Novel Treatment of STING‐Associated Vasculopathy With Onset in Infancy

    by Katarzyna Solarska‐Rydz, Honorata Marczak, Marek Kulus, Katarzyna Krenke

  • Diagnostic Evaluation and Clinical Findings in Children With Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy

    by Honorata Marczak, Katarzyna Krenke, Matthias Griese, Joanna Peradzyńska, Joanna Lange, Marek Kulus, Magdalena Grochowska, Elias Seidl, Jean-Christophe Dubus, Julia Rodler, et al.


  • Serum biomarkers in neuroendocrine cell hyperplasia of infancy

    by Honorata Marczak, Joanna Peradzyńska, Magdalena Paplińska‐Goryca, Paulina Misiukiewicz‐Stępień, Małgorzata Proboszcz, Katarzyna Krenke

    Background: Neuroendocrine cell hyperplasia of infancy (NEHI) is a form of childhood interstitial lung disease of unknown origin associated with hyperplasia of pulmonary neuroendocrine cells (PNECs). Diagnosis is based on the characteristic clinical picture and typical radiological imaging, and, in some cases, on lung biopsies. To date, no biochemical indicators of the disease have been identified.Aim: We aimed to determine biomarkers that could be useful in the management of children diagnosed with NEHI.Methods: Patients with NEHI and healthy children were enrolled. Concentrations of serum biomarkers secreted by PNECs (calcitonin gene‐related peptide and gastrin‐releasing peptide) and biomarkers of the destruction of alveolar capillary membrane (surfactant proteins A and D [SP‐A and SP‐D]; glycoprotein Krebs von den Lungen‐6 [KL‐6]; metalloproteinases 7 and 9 [MMP‐7 and MMP‐9]; tissue inhibitor of metalloprotease 1) were measured.Results: Fifty‐two children with NEHI and 23 healthy children were included in the study. The median age of children with NEHI was 3.9 years. There were no differences in serum levels of biomarkers secreted by PNECs between groups. KL‐6 levels were significantly higher in children with NEHI than in healthy ones (median 119.6 vs. 92.1 U/mL, p = 0.003); however, concentrations of KL‐6 were low in both groups. No significant differences existed between groups for the remaining biomarkers associated with the destruction of the alveolar‐capillary membrane.Conclusions: Measurement of serum biomarkers released by PNECs and those associated with the destruction of the alveolar‐capillary membrane does not appear to be useful in the management of children with NEHI.


  • Open Access

    Health‐related quality scores in childhood interstitial lung disease: Good agreement between patient and caregiver reports

    by Matthias Griese, Nicolaus Schwerk, Julia Carlens, Martin Wetzke, Nagehan Emiralioglu, Nural Kiper, Honorata Marczak, Joanna Lange, Katarzyna Krenke, Nicola Ullmann, et al.

    Introduction: Childhood interstitial lung disease (chILD) is a heterogeneous group of mostly chronic respiratory disorders. Assessment of health‐related quality of life (HrQoL) in chILD has become increasingly important in clinical care and research. The aim of this study was to assess differences between patient‐reported (self) and caregiver‐reported (proxy) HrQoL scores.Methods: This study used data obtained from the chILD‐EU Register. After inclusion (baseline), the patient's health status was followed up at predefined study visits. At each study visit, caregivers and patients were handed validated, age‐specific HrQoL questionnaires. HrQoL data entered at baseline were used to compare self‐ and proxy‐reported HrQoL scores. For the longitudinal analysis, we compared HrQoL scores between the baseline and the next follow‐up visit.Results: No differences between patient‐ and caregiver‐reported HrQoL scores were found for school functioning, chILD‐specific questionnaire score, and physical health summary score. Self‐reported HrQoL scores were higher for the subscales emotional functioning (77.4 vs. 70.7; p < .001), social functioning (81.9 vs. 76.2; p < .001), as well as psycho‐social summary score (76.5 vs. 71.8; p < .001) and total score (74.7 vs. 70.8; <.001). The longitudinal analysis showed that a significant change in a patient‐reported HrQoL score resulted in a significant change in a caregiver‐reported HrQoL score after a mean time of 11.0 months (SD 9.4).Conclusions: We found a good agreement between children‐ and caregiver‐related HrQoL scores. In chILD, caregivers are able to sense changes in children's HrQoL scores over time and may be used as a proxy for children unable to complete HrQoL questionnaires.